<div id="readability-page-1"><div> (RTTNews) - Relay Therapeutics, Inc. (RLAY), a clinical-stage, small-molecule precision medicine company, priced its public offering of 22.92 million shares of common stock at a public offering price of $12 per share. The gross proceeds from the offering are expected to be approximately $275 million. In addition, the firm granted the underwriters a 30-day option to purchase up to an additional 3.44 million shares of its common stock. The offering is expected to close on or about May 22, 2026, subject to closing conditions. Jefferies, TD Cowen, Goldman Sachs &amp; Co. LLC, and Guggenheim Securities are acting as joint book-running managers for the offering. Relay Therapeutics' lead clinical asset is Zovegalisib, a pan-mutant, selective PI3Ka inhibitor, which is currently in a Phase 3 ReDiscover-2 clinical trial in HR+/HER2- metastatic breast cancer. Zovegalisib is also being investigated in a group of genetic disease indications called PIK3CA-driven vascular anomalies. RLAY has traded between $2.75 and $17.32 over the last year. The stock closed Wednesday's trade at $13.02, up 7.87%. RLAY is currently up 0.54% at $13.09. For more such news For More Such Biotech Stock News, visit rttnews.com. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. </div></div>

RLAY

LABU

Relay Therapeutics, Inc. has priced its public offering of 22.92 million shares at $12 each, aiming for gross proceeds of approximately $275 million. The offering includes a 30-day option for underwriters to purchase an additional 3.44 million shares. The expected closing date is around May 22, 2026. Relay's lead asset, Zovegalisib, is in a Phase 3 trial for metastatic breast cancer. The stock closed at $13.02, up 7.87%. Currently, it is trading at $13.09.

nasdaq

Relay Therapeutics

First Trust NYSE Arca Biotech Index Fd

Direxion S&P Biotech Bull 3X

SPDR S&P Biotech

iShares Biotechnology ETF

VanEck Biotech ETF

Invesco Biotechnology & Genome ETF

Jefferies Financial

Toronto Dominion Bank

Goldman Sachs

Nasdaq

GS Hldg R

Relay Therapeutics Prices $275 Mln Offering Of Shares At $12 Per Share